Rally Researcher, Medical Advisory Board member and pediatric oncologist Dr. Michael Kinnaman is the recipient of Rally’s Postdoctoral and Clinical Research Fellow Grant and most recently was awarded a 2020 Young Investigator Grant. In part two of this two-part series, Dr. Kinnaman reveals how our grant has helped fund his research project on characterizing osteosarcoma tumor cells that are resistant to our current therapy with the end goal of discovering new treatment strategies that are specifically targeted towards these resistant tumor cells. Read part one here. Dr. Kinnaman Seeks to Understand the Complexities of Osteosarcoma One of the first patients I saw as a fellow at MSK Kids, Memorial Sloan Kettering’s Pediatric program, was a 12-year-old boy with newly diagnosed osteosarcoma of his right thigh bone. Osteosarcoma is the most common malignant bone tumor in children and...
